Aurinia Pharmaceuticals (AUPH) Long-Term Investments (2020 - 2024)

Aurinia Pharmaceuticals (AUPH) posted Long-Term Investments of $199000.0 for Q2 2024, little changed on a QoQ basis from $199000.0 in Q1 2024.

Aurinia Pharmaceuticals (AUPH) Long-Term Investments (2020 - 2024) Analysis & Trends

Aurinia Pharmaceuticals' Long-Term Investments history runs 4 years deep, the most recent figure standing at $199000.0 for Q2 2024.

Quarterly Long-Term Investments changed N/A year-over-year to $199000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $199000.0 (changed N/A YoY) and the FY2023 annual result came in at $201000.0, changed N/A from the prior year.
Long-Term Investments was $199000.0 for Q2 2024 at Aurinia Pharmaceuticals, roughly flat from $199000.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $24.4 million in Q4 2020 and bottomed at $199000.0 in Q1 2024.
A 4-year average of $6.2 million and a median of $591000.0 in 2023 frame the typical range for Long-Term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Aurinia Pharmaceuticals	2.02 Bn	1.64 Bn	71.20 Mn	-

Download Data